CorMedix Inc. will host an in-person and virtual analyst day in New York on February 10, 2026. The event will include presentations and panels featuring key opinion leaders and the company’s senior management, focusing on updates across CorMedix’s portfolio and pipeline, as well as discussions of key growth drivers and upcoming milestones. The session will highlight the commercial opportunity for the REZZAYO® and DefenCath® programs, both currently in Phase III clinical trials.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. CorMedix Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 9644901) on January 29, 2026, and is solely responsible for the information contained therein.
Comments